Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia
Bionano Genomics announced a publication from Johns Hopkins University demonstrating that optical genome mapping (OGM) can identify structural variants in acute promyelocytic leukemia (APL) that conventional cytogenetic techniques often miss.
The case study showed that OGM detected a PML::RARA fusion variant, which was not identified by karyotyping and non-informative by FISH. This fusion is significant as APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatments like all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, about 13% of APL cases are not properly identified by conventional methods, potentially hindering effective treatment.
OGM's ability to detect these variants aligns with previous findings, suggesting it could be a more reliable alternative for guiding therapy selection and patient management. Bionano's CEO, Erik Holmlin, emphasized that OGM's higher resolution and streamlined workflow make it a promising tool for improving treatment decisions in blood cancer cases.
Bionano Genomics ha annunciato una pubblicazione della Johns Hopkins University che dimostra come la mappatura genomica ottica (OGM) possa identificare varianti strutturali nella leucemia promielocitica acuta (APL) che le tecniche citogenetiche convenzionali spesso trascurano.
Lo studio di caso ha mostrato che l'OGM ha rilevato una variante di fusione PML::RARA, che non è stata identificata dalla cariotyping e risultava non informativa tramite FISH. Questa fusione è significativa poiché l'APL, un sottotipo aggressivo della leucemia mieloide acuta (AML), risponde bene a trattamenti come l'acido all-trans retinoico (ATRA) e l'arsenico triossido (ATO). Tuttavia, circa il 13% dei casi di APL non è identificato correttamente dai metodi convenzionali, il che potrebbe ostacolare un trattamento efficace.
La capacità dell'OGM di rilevare queste varianti è in linea con risultati precedenti, suggerendo che potrebbe essere un'alternativa più affidabile per guidare la selezione della terapia e la gestione del paziente. Erik Holmlin, CEO di Bionano, ha sottolineato che la maggiore risoluzione dell'OGM e il flusso di lavoro semplificato ne fanno uno strumento promettente per migliorare le decisioni di trattamento nei casi di cancro del sangue.
Bionano Genomics anunció una publicación de la Universidad Johns Hopkins que demuestra que el mapeo genómico óptico (OGM) puede identificar variantes estructurales en la leucemia promielocítica aguda (APL) que a menudo se pierden con las técnicas citogenéticas convencionales.
El estudio de caso mostró que el OGM detectó una variante de fusión PML::RARA, que no fue identificada mediante cariotipado y fue no informativa por FISH. Esta fusión es significativa ya que la APL, un subtipo agresivo de la leucemia mieloide aguda (AML), responde bien a tratamientos como el ácido retinoico todo trans (ATRA) y el trióxido de arsénico (ATO). Sin embargo, alrededor del 13% de los casos de APL no son identificados correctamente por métodos convencionales, potencialmente obstaculizando un tratamiento eficaz.
La capacidad del OGM para detectar estas variantes está alineada con hallazgos previos, sugiriendo que podría ser una alternativa más confiable para guiar la selección de terapia y el manejo del paciente. Erik Holmlin, CEO de Bionano, enfatizó que la mayor resolución del OGM y el flujo de trabajo optimizado lo convierten en una herramienta prometedora para mejorar las decisiones de tratamiento en casos de cáncer en la sangre.
바이오나노 제노믹스는 존스 홉킨스 대학이 발표한 연구 결과를 발표하였으며, 이는 광유전자 mapping (OGM)이 일반적인 세포 유전 기법들이 종종 놓치는 급성 전구세포 백혈병 (APL)의 구조 변종을 식별할 수 있음을 입증합니다.
사례 연구는 OGM이 카리오타이핑으로는 식별되지 않고 FISH로는 비정보성인 PML::RARA 융합 변종을 감지하였음을 보여주었습니다. 이 융합은 APL이 급성 골수성 백혈병 (AML)의 공격적인 하위 유형으로 전환형 레티노산 (ATRA)과 트리옥시드 비소 (ATO)와 같은 치료에 잘 반응하기 때문에 중요합니다. 그러나 약 13%의 APL 사례는 기존 방법으로 적절하게 식별되지 않아 효과적인 치료에 방해가 될 수 있습니다.
OGM의 이러한 변종 감지 능력은 이전 결과와 일치하여 치료 선택 및 환자 관리의 안내에 있어 보다 신뢰할 수 있는 대안이 될 수 있음을 시사합니다. 바이오나노의 CEO인 에릭 홀민은 OGM의 높은 해상도와 간소화된 작업 흐름이 혈액암의 치료 결정을 개선하는 유망한 도구가 될 것이라고 강조했습니다.
Bionano Genomics a annoncé une publication de l'université Johns Hopkins démontrant que le mapping génomique optique (OGM) peut identifier des variants structurels dans la leucémie promyélocytaire aiguë (APL) que les techniques cytogénétiques conventionnelles passent souvent sous silence.
L'étude de cas a montré que l'OGM a détecté un variant de fusion PML::RARA, qui n'a pas été identifié par le caryotypage et qui était non informatif par FISH. Cette fusion est significative car l'APL, un sous-type agressif de leucémie myélomonocytique aiguë (AML), répond bien à des traitements tels que l'acide tout-trans-rétinoïque (ATRA) et le trioxyde d'arsenic (ATO). Cependant, environ 13 % des cas d'APL ne sont pas correctement identifiés par les méthodes conventionnelles, ce qui pourrait entraver un traitement efficace.
La capacité de l'OGM à détecter ces variants s'aligne avec des découvertes précédentes, suggérant qu'il pourrait être une alternative plus fiable pour guider le choix de la thérapie et la gestion des patients. Erik Holmlin, PDG de Bionano, a souligné que la résolution plus élevée de l'OGM et le flux de travail rationalisé en font un outil prometteur pour améliorer les décisions de traitement dans les cas de cancer du sang.
Bionano Genomics hat eine Veröffentlichung der Johns Hopkins University angekündigt, die zeigt, dass optische Genomkartierung (OGM) strukturelle Varianten in akuter Promyelocyten-Leukämie (APL) erkennen kann, die konventionelle zytogenetische Techniken oft übersehen.
Die Fallstudie zeigte, dass OGM eine PML::RARA Fusion Variante entdeckte, die durch Karyotypisierung nicht identifiziert wurde und bei FISH nicht informativ war. Diese Fusion ist signifikant, da APL, ein aggressiver Subtyp der akuten myeloischen Leukämie (AML), gut auf Behandlungen wie all-trans Retinsäure (ATRA) und Arsentrioxid (ATO) anspricht. Allerdings werden etwa 13 % der APL-Fälle von konventionellen Methoden nicht korrekt identifiziert, was eine effektive Behandlung behindern kann.
Die Fähigkeit von OGM, diese Varianten zu erkennen, steht im Einklang mit früheren Erkenntnissen und deutet darauf hin, dass es eine verlässlichere Alternative zur Unterstützung der Therapieauswahl und Patientenmanagement sein könnte. Erik Holmlin, CEO von Bionano, betonte, dass die höhere Auflösung von OGM und der optimierte Arbeitsablauf es zu einem vielversprechenden Werkzeug zur Verbesserung der Behandlungsentscheidungen bei Blutkrebsfällen machen.
- OGM identified a PML::RARA fusion variant in APL that conventional methods missed.
- OGM detected variants in about 13% of APL cases where conventional cytogenetics failed.
- Potential for OGM to improve therapy selection and patient management in blood cancer.
- None.
Insights
For simplified understanding: Imagine trying to find a specific page in a book with some pages stuck together - traditional methods (karyotyping and FISH) sometimes can't separate these pages to find what they're looking for. OGM is like having an X-ray machine that can see through the stuck pages, revealing hidden information that guides doctors to the right treatment.
However, BNGO's extremely low market cap of
Breaking down the market opportunity: APL represents about
However, the micro-cap status of BNGO (
- A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in acute promyelocytic leukemia (APL)
- The researchers reported that APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) classes of targeted therapies but that in about
13% of cases of APL, conventional cytogenetics fails to identify the variant(s) that indicate(s) these treatment - Identification of this PML::RARA fusion variant by OGM is consistent with previously reported findings which show that OGM can detect variants found by standard cytogenetics and can also find additional variants that are missed by these techniques
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication from the Johns Hopkins University School of Medicine in Genes showing that optical genome mapping (OGM) identifies a variant in an aggressive form of acute myelogenous leukemia (AML) known as acute promyelocytic leukemia, or APL. This variant is often missed by conventional cytogenetic techniques.
In the case study, researchers reported that OGM detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in APL. According to the publication, APL is a subtype of AML that responds well to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) classes of targeted therapies but that in about
Erik Holmlin, president and chief executive officer of Bionano, commented, “This case study supports the view that the standard of care techniques used for devastating diseases like blood cancer are insufficient to reliably guide therapy selection and patient management, due to their tendency to miss actionable variants for a significant fraction of cases. It also shows that OGM, with its higher resolution, streamlined workflow and ability to find more variants, can be a suitable alternative to these techniques, and could result in better therapy selection and patient management decisions.”
The full research publication is available at: Optical Genome Mapping Reveals Complex and Cryptic Rearrangement Involving PML::RARA Fusion in Acute Promyelocytic Leukemia.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “ability,” “can,” “could,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s ability to detect variants undetected by traditional cytogenetic techniques; OGM’s ability to detect the PML::RARA fusion in acute promyelocytic leukemia (APL); the potential utility that variants detected by OGM may have in therapy selection or patient management decisions; the utility of OGM for uses described in the publication referenced in this press release; the utility and ability of OGM to detect variants missed by traditional cytogenetic techniques; and other statements that are not historical facts. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, supply chain disruptions, global pandemics, inflation, and the ongoing conflicts between Ukraine and Russian and Israel and Hamas, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the failure of OGM to detect variants undetected by traditional cytogenetic techniques; the failure of OGM to detect the PML::RARA fusion in acute promyelocytic leukemia (APL); the failure of OGM to prove useful in therapy selection or patient management decisions; the failure of OGM to be useful for the applications described in the publication referenced in this press release; the failure of OGM to detect variants missed by traditional cytogenetic techniques; future publications that contradict the findings of the publication referenced in this press release; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; our ability to effectively manage our uses of cash, and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com
FAQ
What is the significance of the PML::RARA fusion variant identified by OGM in APL?
How does OGM improve the detection of variants in acute promyelocytic leukemia (APL)?
What percentage of APL cases are not properly identified by conventional cytogenetics?
How does OGM's detection capability compare to standard cytogenetics?
What are the potential benefits of using OGM for blood cancer treatment decisions?
